The blog
Clinical trial results, TGA regulatory progress and research updates on retatrutide and the wider peptide space — explained for Australians.
14 September 2026 · retatrutide · mounjaro · tirzepatide · australia · clinical trials
Retatrutide vs Mounjaro in Australia: why the 28.3% vs 20.9% comparison isn't real, and what the TRIUMPH-5 head-to-head trial is actually testing.
Read more →13 September 2026 · retatrutide · phase 3 · clinical trials · type 2 diabetes · research
The first retatrutide phase 3 trial to clear peer review is TRANSCEND-T2D-1 in The Lancet - a diabetes study, not the obesity headline. What it shows.
Read more →12 September 2026 · retatrutide · side effects · safety · triumph · australia
Retatrutide side effects go beyond nausea. Phase 3 TRIUMPH surfaced dysesthesia in 20.9% at 12mg — a signal absent from phase 2. The full data, and the Australian gap.
Read more →11 September 2026 · retatrutide · sleep apnoea · triumph-1 · clinical trials · tirzepatide
Retatrutide results from the TRIUMPH-1 sleep apnoea basket trial: AHI cut 60.6% at 12mg in 243 adults. What it means, and why Australia has a precedent.
Read more →10 September 2026 · retatrutide · price · australia · pbs · access
There is no retatrutide price in Australia yet. But two 2026 decisions - Lilly's PBS walk-away and Wegovy's narrow PBAC yes - show how cost will be set.
Read more →9 September 2026 · retatrutide · fda approval · regulatory · eli lilly · retatrutide news
Retatrutide FDA approval partly hinges on a court fight over 39 amino acids. Lilly v FDA reaches the Seventh Circuit on 24 September 2026 - here's why.
Read more →29 August 2026 · retatrutide · australia · access · tga · clinical trials
Lilly opened early access to retatrutide on 3 August 2026. Here's how to get retatrutide in Australia today, and why that news doesn't change the local answer.
Read more →28 August 2026 · retatrutide · retatrutide news · real-world evidence · triumph-1 · tirzepatide
Retatrutide news: a new US real-world analysis found non-trial users lost about 7.2% of body weight at 6-12 months, versus 15.5% in a trial cohort.
Read more →27 August 2026 · retatrutide · tga approval · australia · regulation · weight loss
Retatrutide TGA approval explained: Australia's regulator only acts when a sponsor files. What that means, the three pathways, and why PBS is separate.
Read more →26 August 2026 · retatrutide · triumph-3 · clinical trials · cardiovascular · phase 3
Retatrutide phase 3 TRIUMPH-3 hit 22.6% weight loss in adults with heart disease - but it was never built to prove cardiovascular risk reduction. Here's why.
Read more →25 August 2026 · retatrutide · australia · anti-doping · tga · clinical-trials
Retatrutide australia status in 2026: still investigational, not TGA-approved, and a real drug-testing grey zone for athletes. Here is what we know now.
Read more →24 August 2026 · retatrutide · mechanism · glucagon · triple agonist · clinical trials
Retatrutide is the only triple agonist in late-stage trials. Here's how its glucagon arm may burn energy, not just curb appetite - and what's still unproven.
Read more →23 August 2026 · retatrutide · mounjaro · tirzepatide · australia · comparison
Retatrutide vs Mounjaro in Australia: should you wait for the triple agonist or start tirzepatide now? What TRIUMPH-1's 28.3% really means for the choice.
Read more →22 August 2026 · retatrutide · phase 3 · triumph · type 2 diabetes · weight loss
Retatrutide phase 3 TRIUMPH-2 showed 20.8% weight loss in type 2 diabetes vs 28.3% in TRIUMPH-1. Here is why the gap exists and what it means.
Read more →21 August 2026 · retatrutide · australia · availability · regional health · glp-1
Retatrutide availability in Australia won't arrive everywhere at once. Why prescriber maps, cold chain and telehealth rules decide your real wait time.
Read more →20 August 2026 · retatrutide · manufacturing · fda · triumph · supply
Retatrutide news: Lilly plans a Q1 2027 FDA filing, but its $3.5B retatrutide plant opens in 2031. Why manufacturing, not approval, sets the timeline.
Read more →19 August 2026 · retatrutide side effects · triumph trials · retatrutide australia · tolerability · glp-1
New TRIUMPH-2 and TRIUMPH-3 topline data sharpens the retatrutide side effects picture - and what dose escalation could mean for Australians later.
Read more →18 August 2026 · retatrutide · triumph-1 · weight loss results · bmi · clinical trials
New TRIUMPH-1 detail: 65.3% on retatrutide 12mg fell below BMI 30. Why these retatrutide weight loss results matter more than the 28.3% headline.
Read more →17 August 2026 · retatrutide vs wegovy · retatrutide australia · tga · oral glp-1 · obesity
Retatrutide vs Wegovy in Australia: the triple agonist wins on trial data, but oral obesity drugs are at the TGA first. What that means for access in 2026-27.
Read more →16 August 2026 · retatrutide · tirzepatide · glucagon · liver · clinical trials
Retatrutide vs tirzepatide isn't just about weight loss. The glucagon receptor targets the liver - here's what the phase 2a liver fat data really showed.
Read more →15 August 2026 · retatrutide australia · clinical trials · tga · early access · triumph
Lilly opened retatrutide early access overseas, but not here. What retatrutide Australia access really looks like in 2026 — trial sites, TGA pathways and timing.
Read more →14 August 2026 · retatrutide · retatrutide results · triumph · clinical trials · obesity
New TRIUMPH-2 and TRIUMPH-3 retatrutide results show 20.8% and 22.6% weight loss, not 28.3%. Why the same drug gives different numbers in different patients.
Read more →13 August 2026 · retatrutide · retatrutide australia · weight maintenance · glp-1 · obesity
Retatrutide Australia: the maintenance question nobody plans for — what trial data suggests happens after you stop, and how Aussies can prepare now.
Read more →12 August 2026 · retatrutide dosing · triumph trials · phase 3 · obesity · glp-1
Retatrutide dosing explained: why every phase 3 headline reflects the top dose, what TRIUMPH-2 and TRIUMPH-3 showed, and why the dose drives cost and tolerability.
Read more →11 August 2026 · retatrutide · australia · body composition · muscle · glp-1
Retatrutide Australia update: what the body composition data shows about fat vs muscle loss with the triple-agonist, and what Aussies can do before TGA approval.
Read more →7 August 2026 · retatrutide australia · triumph-3 · pbs · cardiovascular · tga
TRIUMPH-3 tested retatrutide in adults with obesity and heart disease, the same group backed for PBS subsidy. What it means for retatrutide Australia access.
Read more →6 August 2026 · retatrutide · fda · regulatory · eli lilly · obesity
When will retatrutide be available? Lilly reconfirmed a Q1 2027 FDA filing, but an unresolved biologic-vs-drug fight could shape the timeline and price.
Read more →5 August 2026 · retatrutide australia · type 2 diabetes · pbs · tga · transcend-t2d
Retatrutide Australia update: why the TRANSCEND-T2D-1 diabetes data may decide TGA registration and PBS subsidy here before any weight-loss listing.
Read more →4 August 2026 · retatrutide · expanded access · fda approval · obesity · eli lilly
Eli Lilly has opened a formal retatrutide expanded access programme. What the four criteria are, and what it means for retatrutide FDA approval timing.
Read more →3 August 2026 · retatrutide australia · preparation · tga approval · glp-1 · muscle mass
Retatrutide australia access is years away. Here are five things to do now — GP baseline, protein, resistance training, side-effect prep and budgeting.
Read more →2 August 2026 · retatrutide australia · how to get retatrutide · tga · clinical trials · access pathways
How to get retatrutide in Australia in 2026: the clinical trial route, why the Special Access Scheme can't help yet, and what changes once Lilly files in 2027.
Read more →2 August 2026 · retatrutide · availability · tga · pbs · australia
Retatrutide availability in Australia won't be one switch. New TRIUMPH-2 and TRIUMPH-3 data shows who is likely to reach the front of the access queue.
Read more →1 August 2026 · retatrutide · price · australia · pbs · cost
Retatrutide has no Australian price yet, but Mounjaro and Wegovy give real benchmarks. Three cost scenarios, the PBS question and the 2027 filing timeline.
Read more →31 July 2026 · retatrutide · osteoarthritis · triumph-4 · clinical-trials · australia
TRIUMPH-4 showed retatrutide cut weight up to 28.7% and eased knee osteoarthritis pain. What that could mean for Australians on joint surgery waitlists.
Read more →31 July 2026 · retatrutide · side effects · triumph-1 · tga · australia
Retatrutide side effects by dose: TRIUMPH-1 nausea, vomiting and discontinuation rates, dysesthesia explained, and why 4mg may matter most for Australians.
Read more →31 July 2026 · retatrutide · tga approval · pbs · australia · regulation
Retatrutide TGA approval explained: the five regulatory gates from phase 3 to ARTG registration, PBAC subsidy and real Australian availability. No hype, just the process.
Read more →31 July 2026 · comparison · ozempic · mounjaro · weight loss
Retatrutide targets three metabolic receptors — Ozempic targets one, Mounjaro two. Here's how the triple-agonist compares on weight loss, mechanism, side effects and Australian availability.
Read more →30 July 2026 · news · trials · weight-loss · metabolic · cardiovascular · research · eli-lilly · triumph-program
The pivotal TRIUMPH-1 Phase 3 trial confirms retatrutide delivered up to 28.3% average weight loss at 80 weeks, with significant cardiometabolic benefits — here's what the data means.
Read more →30 July 2026 · news · announcement
News, clinical trial updates and TGA regulatory progress on Retatrutide — written for Australians.
Read more →Stay informed
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.